Published January 1, 2020
| Version v1
Journal article
Open
Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study
Creators
- 1. Hacettepe Univ, Dept Pediat Neurol, Ankara, Turkey
- 2. Marmara Univ, Fac Pharm, Istanbul, Turkey
- 3. Analyt Chem, Istanbul, Turkey
- 4. Marmara Univ, Sch Appl Disciplines, Istanbul, Turkey
- 5. Hacettepe Univ, Dept Radiol, Ankara, Turkey
Description
Background: Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. We aimed to investigate the safety and efficacy of aprepitant in patients with subacute sclerosing panencephalitis.
Files
bib-da6c7153-8111-41c9-ad5b-cb4872136539.txt
Files
(285 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:02d467fff9213f55ccc884020ec31f26
|
285 Bytes | Preview Download |